Long-Term Outcomes in Antibody-Negative Autoimmune Encephalitis: A Retrospective Study

Neurology. 2024 Oct 8;103(7_Supplement_1):S83-S84. doi: 10.1212/01.wnl.0001051560.74390.09. Epub 2024 Oct 8.

Abstract

Objective: To characterize the long-term outcomes of patients with "possible only" or "probable" autoimmune encephalitis (AE).

Background: Despite comprising one-third of AE cases, antibody-negative cases lacking typical AE-defining features are understudied.

Design/methods: We conducted a retrospective analysis of adult patients evaluated at a tertiary center neuroimmunology practice from 2006 to 2020, meeting diagnostic criteria for "possible only" or "probable but antibody-negative" AE, with at least one year of follow-up. All patients underwent neural antibody testing.

Results: Forty-five patients (median age, 61 years [range, 20-88]; female, 21 [47%]) were included, with a median follow-up of 36 months (range, 12-174). A change in diagnosis was noted in six additional patients, who were excluded from further analysis, with only two receiving a non-autoimmune diagnosis during follow-up. The majority (41/45 [91%]) presented with significant disability (modified Rankin Scale [mRS] ≥3) at baseline. CSF was inflammatory in 20/44 (45%) and MRI was abnormal in 21/45 (47%). Unclassified neural-specific IgG staining on tissue-based assay was detected in five (11%). Two cases (4%) had a paraneoplastic cause. The median time from onset to immunotherapy initiation was two months (range, 0-21), resulting in at least partial improvement in all 44 (98%) treated cases. Clinical relapses occurred in 14/45 (31%). At last follow-up, the most common symptoms were memory dysfunction (31/45 [69%]), attention deficits (17/45 [38%]), gait instability (13/45 [29%]), and visuospatial dysfunction (10/45 [22%]). Most patients achieved independence (median mRS, 2 [range, 0-6]); however, 11 patients had poor neurological outcome (mRS ≥3). Higher mRS score and gait assistance requirement at three months were predictive of poor outcome (P ≤0.01).

Conclusions: Despite significant disability at initial stages, patients with antibody-negative but clinically presumed AE show potential for improvement with immunotherapy, highlighting the importance of early intervention. Early functional status and gait assistance requirements may assist in predicting long-term prognosis.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Autoantibodies / blood
  • Autoantibodies / cerebrospinal fluid
  • Autoimmune Diseases of the Nervous System / diagnosis
  • Autoimmune Diseases of the Nervous System / immunology
  • Autoimmune Diseases of the Nervous System / physiopathology
  • Autoimmune Diseases of the Nervous System / therapy
  • Encephalitis* / diagnosis
  • Encephalitis* / immunology
  • Female
  • Follow-Up Studies
  • Hashimoto Disease* / diagnosis
  • Hashimoto Disease* / immunology
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Young Adult

Substances

  • Autoantibodies

Supplementary concepts

  • Hashimoto's encephalitis